Santhera Confident Of Raxone DMD Success Despite Setbacks

 
• By Kevin Grogan

The Swiss company believes it has collected sufficient new data on Raxone for Duchenne muscular dystrophy to convince regulators and hopes to file for that indication on both sides of the Atlantic by the end of the first quarter of 2019.

Fingers crossed
Santhera hopes for better luck with regulators • Source: Shutterstock

More from Rare Diseases

More from Scrip